90 patents
Page 5 of 5
Utility
RAR selective agonists in combination with immune modulators for cancer immunotherapy
13 Jan 20
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 22 Jul 19
Utility
Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
30 Dec 19
Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 30 May 19
Utility
Treatment of Autoimmune Diseases with Combinations of RXR Agonists and Thyroid Hormones
18 Dec 19
The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 30 Oct 16
Utility
Treatment of Cancer with Combinations of RXR Agonists and Thyroid Hormones
4 Dec 19
The present specification provides methods of treating cancer with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 30 Oct 16
Utility
Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
25 Nov 19
Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 20 Feb 19
Utility
Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
25 Nov 19
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 29 Aug 18
Utility
Rar Selective Agonists In Combination with Immune Modulators for Cancer Immunotherapy
13 Nov 19
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 22 Jul 19
Utility
Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
11 Nov 19
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 30 Jan 19
Utility
Rar Selective Agonists In Combination with Immune Modulators for Cancer Immunotherapy
16 Oct 19
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 25 Jun 19
Utility
Treatment of Muscular Disorders with Combinations of RXR Agonists and Thyroid Hormones
2 Oct 19
The present specification provides methods of treating a muscular disorder with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 30 Oct 16